


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>4</sup> : C07K 15/00, C12P 21/00 C12P 435/68, C12N 15/00 C12N 435/172, 260/112	A1	(11) International Publication Number: <b>WO 86/ 04589</b> (43) International Publication Date:   14 August 1986 (14.08.86)
(21) International Application Number:     PCT/US86/00223 (22) International Filing Date:       30 January 1986 (30.01.86) (31) Priority Application Number:                          696,647 (32) Priority Date:                      30 January 1985 (30.01.85) (33) Priority Country:                                                  US		(74) Agent: CLARK, Paul, T.; Fish & Richardson, One Financial Center, Boston, MA 02111 (US).  (81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent).
(71)(72) Applicants and Inventors: REDDY, Vemuri, B. [IN/US]; 2 John McQuinn Circle, Framingham, MA 01701 (US). HSIUNG, Nancy [US/US]; 590 4A Washington Street, Wellesley, MA 02181 (US). BECK, Anton, K. [CH/US]; 42 Crosbey Road, Chestnut Hill, MA 02167 (US). BERNSTINE, Edward, George [US/US]; 4 Longfellow Place #2005, Boston, MA 02114 (US).		Published <i>With international search report.</i>

**(54) Title:** FSH

**(57) Abstract**

Biologically active heterodimeric human FSH composed of an alpha subunit and a beta subunit, each subunit being synthesized by a cell having an expression vector containing heterologous DNA encoding the subunit.



***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

FSHBackground of the Invention

This application is a continuation-in-part of copending application S.N. 548,211 entitled "Heteropolymeric Protein" filed November 2, 1983.

5 This invention relates to the use of recombinant DNA techniques to produce heteropolymeric proteins.

Various polypeptide chains have been expressed, via recombinant DNA technology, in host cells such as bacteria, yeast, and cultured mammalian cells. Fiddes, J. C. and  
10 Goodman, H. M. (1979) Nature Vol. 281, pg. 351-356 and Fiddes, J. C. and Goodman, H. M. (1980) Nature Vol. 286, pg. 684-687 describe the cloning of, respectively, the alpha and beta subunits of human choriogonadotropin (hCG).

Kaname US Patent 4,383,036 describes a process for  
15 producing hCG in which human lymphoblastoid cells are implanted into a laboratory animal, harvested from the animal, and cultured in vitro; accumulated hCG is then harvested from the culture.

Summary of the Invention

20 In general the invention features the biologically active heterodimeric human fertility hormone follicle stimulating hormone ("FSH") which includes an alpha subunit and a beta subunit, each subunit being synthesized by a cell having

an expression vector containing heterologous DNA encoding the subunit.

The term "expression vector" refers to a cloning vector which includes heterologous (to the vector) DNA under the control of sequences which permit expression in a host cell. Such vectors include replicating viruses, plasmids, and phages. Preferred vectors are those containing at least the 69% transforming region, and most preferably all, of the bovine papilloma virus genome.

10       The invention permits the production of biologically active heterodimeric FSH from a single culture of transformed cells. The production of both subunits of FSH in the same cell eliminates the necessity of recombining subunits from separate cultures to assemble an active heterodimeric molecule. The  
15 system also allows production of FSH, in a single culture, which undergoes, in the culture, post-translational modification, e.g. glycosylation and proteolytic processing, for activity or stability.

In preferred embodiments, each expression vector is  
20 autonomously replicating, i.e., not integrated into the chromosome of the host cell. The use of autonomously replicating expression vectors prevents undesirable influence of the desired coding regions by control sequences in the host chromosome.

Other advantages and features of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

#### Description of the Preferred Embodiments

5 We turn now to the preferred embodiments of the invention, first briefly describing the drawings thereof.

#### Drawings

Fig. 1 is a diagrammatic illustration of the construction of the plasmid pRF375.

10 Fig. 2 is a partial restriction map of the lambda clone 15B and the beta FSH-containing 6.8 kb EcoRI-BamHI fragment that is inserted into pBR322.

Fig. 3 is a partial restriction map of the beta FSH coding region and the BamHI fragment that is inserted into a  
15 BPV based expression vector.

Fig. 4 is a diagrammatic illustration of the construction of the BPV-containing plasmid CL28FSH2.8BPV, encoding the beta subunit of FSH.

#### Structure

20 The cloning vectors of the invention have the general structure recited in the Summary of the Invention, above. Preferred vectors have the structures shown in the Figures, and are described in more detail below.

## Construction of Cloning Vectors

### Isolation of cDNA Clones Encoding the

### Common Alpha Subunit

In order to produce the heterodimeric FSH of the  
5 invention, the alpha subunit of human chorionic gonadotropin  
(hCG) first is isolated; the alpha subunit is common to the  
fertility hormones hCG, luteinizing hormone (LH), and FSH.

All of the techniques used herein are described in  
detail in Maniatis et al. (1982) Molecular Cloning: A  
10 Laboratory Manual (Cold Spring Harbor Laboratory), hereby  
incorporated by reference.

RNA is extracted from placental tissue by the  
following method. Homogenization of the tissue is carried out  
in a 1:1 mixture of phenol:100mM Na-acetate (pH 5.5) containing  
15 1mM EDTA, that has been warmed to 60°C. for 20 min. After  
cooling on ice for 10 min., the phases are separated by  
centrifugation. The hot phenol extraction is repeated twice  
more followed by two extractions with chloroform.

RNA is precipitated from the final aqueous phase by  
20 the addition of 2.5 volumes of ethanol.

In order to enrich for poly A+ mRNA, placental RNA is  
passed over oligo (dT)-cellulose in 0.5M NaCl buffered with  
10mM Tris-HCl, pH 7.5, and washed with the same solution. Poly  
A+ mRNA is eluted with 10mM Tris-HCl (pH 7.5), 1mM EDTA, 0.05%  
25 SDS and precipitated twice with ethanol. Typical initial

yields are 1.5-2.0 mg of total RNA per g of tissue, of which about 2% is poly A+ mRNA.

Placental cDNA libraries are constructed by reverse transcription of placental mRNA, second strand synthesis using  
5 E. coli DNA polymerase I (large fragment), treatment with SI nuclease, and homopolymer tailing (dC) with terminal deoxynucleotidyl transferase; all such procedures are by conventional techniques.

In a typical preparation, 20-30% conversion of mRNA to  
10 single strand (ss) cDNA; 70% resistance to digestion with nuclease S1 after second strand synthesis; and dC "tails" of ten to twenty-five bases in length, are obtained. These cDNA molecules are then annealed to DNA fragments of the plasmid pBR 322, which has been digested with PstI, and to which dG "tails"  
15 have been added. These recombinant plasmids are then used to transform E. coli cells to generate a cDNA library (transformed cells are selected on the basis of tetracycline resistance).

In order to identify the human alpha hCG clone, a 219 bp fragment of a mouse alpha thyroid stimulating hormone (TSH)  
20 clone is used as a hybridization probe. This probe has 77% sequence homology with the human clone. It is radioactively labeled by nick translation and hybridized to the cDNA library under conditions that take into account the extent of homology. Strongly hybridizing clones are analyzed by  
25 restriction mapping and clones containing the complete coding sequence of alpha hCG are verified by DNA sequencing.

Construction of Plasmid pRF375

Referring to Fig. 1, the plasmid CL28 (identical to plasmid JYMMT(E); Hamer et al. (1983) J. Mol. Applied Gen. 1, 273-288), containing the murine metallothionein promoter, SV40 DNA, and pBR322 sequences, is cut with the restriction endonuclease BglII. At this site is inserted the cDNA clone of alpha hCG, containing untranslated regions of about 10 and 220 bp at its 5' and 3' ends, respectively. This clone has been genetically engineered by the addition of synthetic BamHI linkers at its termini.

The resulting plasmid pRF302 is digested with restriction enzymes BamHI and SalI to release the SV40 DNA sequence.

Plasmid pB2-2, which contains the entire BPV genome, and some pBR322 sequences, is digested with BamHI and SalI to yield the BPV genome with BamHI/SalI ends; this fragment is ligated into pRF302 containing the metallothionein-hCG sequences.

Following transformation of E. coli, plasmid pRF375 is identified and isolated. It encodes the common alpha subunit under the control of the mouse metallothionein promoter.

Isolation of the Human beta FSH Gene

A human genomic library in phage lambda (Lawn et al., 1978, Cell 15, p. 1157-1174) is screened using "guessed" long



probes. The idea behind such probes, set forth in Jaye et al. (1983) Nucleic Acids Research 11(8), 2325, is that if the amino acid sequence of a desired protein is at least partially known, a long probe can be constructed in which educated guesses are made as to the triplet encoding any amino acid which can be encoded by more than one, and not more than four, different triplets. Any correct guesses increase the amount of homology, and improve the specificity, of the results.

To isolate desired regions of DNA, two labeled 45-mer probes are used: TB36, homologous with amino acids 56-70 of human beta FSH; and TB21, homologous with amino acids 73-87. These probes have the following nucleotide compositions (corresponding amino acids are also given):

TB36: Val-Tyr-Glu-Thr-Val-Lys-Val-

15 (AA56-70) 3' CAC ATG CTC TGG CAC TCT CAC

Pro-Gly-Cys-Ala-His-His-Ala-Asp

GGT CCG ACG CGG GTG GTG CGA CTG 5'

TB21: Tyr-Thr-Tyr-Pro-Val-Ala-Thr-

(AA73-87) 3' ATG TGC ATG GGT CAC CGA TGT

20 Glu-Cys-His-Cys-Gly-Lys-Cys-Asp

CTC ACA GTG ACG CCG TTT ACG CTG 5'

The above probes are used to screen the human genomic library as follows. TB21 is labeled with  $^{32}\text{P}$  and used to screen approximately  $5 \times 10^5$  lambda plaques on duplicate filters by the in situ plaque hybridization technique of Benton and Davis (1977) Science 196, 180-182. The prehybridization solution is maintained at  $55^\circ\text{C}$  for several hours and has the following composition: 0.75M NaCl; 0.15M Tris/HCl, pH 8.0; 10mM EDTA; 5 x Denhardt's Solution; 0.1% sodium pyrophosphate; 0.1% SDS; 100 microgram/ml E. coli t-RNA. The hybridization solution has the same composition except that it is maintained overnight at  $45^\circ\text{C}$ , and contains labeled probe in a concentration of about  $0.5 \times 10^6$  cpm/ml. After hybridization, the filters are washed four times in 1 X SSC (= 0.15M NaCl, 0.015M Na<sub>2</sub>-citrate) and exposed to x-ray film.

This screening procedure yields 50 plaques which hybridize to TB21 on both sets of filters. These 50 individual plaques are picked and combined into 10 culture pools containing 5 plaques each. The 10 cultures are grown and DNA is isolated from 50ml phage lysates. This DNA is then digested with EcoRI and fractionated on two identical 1% agarose gels, after which it is transferred to nitrocellulose paper according to the method of Southern (1975) J. Mol. Biol. 98, 503-517.

The DNAs on the two filters are hybridized to <sup>32</sup>P labeled TB21 and TB36, respectively. Individual plaques from the pool containing a restriction fragment which strongly hybridizes to both probes are then  
5 screened according to the above procedure, except that the DNAs are digested with EcoRI, BamHI, and EcoRI plus BamHI. In this way the 6.8kb EcoRI-BamHI fragment containing human beta FSH is isolated.

A partial restriction map of clone 15B,  
10 containing the 6.8kb EcoRI-BamHI fragment, is shown in Fig. 2. In order to locate the position of the beta FSH sequences within the clone, the 6.8 kb EcoRI-BamHI fragment of clone 15B is subcloned into pBR322 to yield plasmid p15B6.8R/B (Fig. 2). p15B6.8R/B is then  
15 digested with various restriction enzymes and the products are fractionated by agarose gel electrophoresis using conventional methods. The DNA is blotted to nitrocellulose paper and hybridized to fragments of a porcine beta FSH cDNA clone labeled with <sup>32</sup>P by nick  
20 translation.

As shown in Fig. 2, the porcine beta FSH probe hybridizes to only two fragments of the human DNA, namely a 1.1kb HindIII-KpnI and a 1.4kb PstI fragment. Partial DNA sequencing of these two fragments shows that  
25 this DNA indeed codes for human beta FSH and that the

entire coding region for beta FSH is contained in these two fragments.

As shown by the restriction map of Fig. 3, the beta FSH coding sequence is interrupted by an  
 5 intervening sequence of approximately 1.6kb between amino acids 35 and 36 of mature beta FSH. The nucleotide sequence of the entire human beta FSH coding region and some of the flanking and intervening sequences are given below. The amino acid sequence  
 10 deduced from the nucleotide sequence is given for the coding region.

```

      30
GCT TAC ATA ATG AIT ATC GTT CTT TGG TTT CTC AGT TTC TAG TGG GCT TCA TTG TTT GCT 60

      90
TCC CAG ACC AGG ATG AAG ACA CTC CAG TTT TTC TTC CTT TTC TGT TGC TGG AAA GCA ATC 120
      Met Lys Thr Leu Gln Phe Phe Phe Leu Phe Cys Cys Trp Lys Ala Ile

      150
TGC TGC AAT AGC TGT GAG CTG ACC AAC ATC ACC ATT GCA ATA GAG AAA GAA GAA TGT 180
      Cys Cys Asn Ser Cys Glu Leu Thr Asn Ile Thr Ile Ala Ile Glu Lys Glu Glu Cys Arg

      210
TTC TGC ATA AGC ATC AAC ACC ACT TGG TGT GCT GGC TAC TGC TAC ACC AGG GTA GGT ACC 240
      Phe Cys Ile Ser Ile Asn Thr Thr Trp Cys Ala Gly Tyr Cys Tyr Thr Arg

      270
ATG TTA GAG CAA GCA GTA TTC AAT TTC TGT CTC ATT TTG ACT AAG CTA AAT AGG AAC 300

      330
TTC CAC AAT ACC ATA ACC TAA CTC TCT TCT TAA ACT CCT CAG GAT CTG GTG TAT AAG GAC 360
      Asp Leu Val Tyr Lys Asp

      390
CCA GCC AGG CCC AAA ATC CAG AAA ACA TGT ACC TTC AAG GAA CTG GTA TAT GAA ACA GTG 420
      Pro Ala Arg Pro Lys Ile Gln Lys Thr Cys Thr Phe Lys Glu Leu Val Tyr Glu Thr Val

      450
AGA GTG CCC GGC TGT GCT CAC CAT GCA GAT TCC TTG TAT ACA TAC CCA GTG GCC ACC CAG 480
      Arg Val Pro Gly Cys Ala His His Ala Asp Ser Leu Tyr Thr Tyr Pro Val Ala Thr Gln

      510
TGT CAC TGT GGC AAG TGT GAC AGC GAC AGC ACT GAT TGT ACT GTG CGA GGC CTG GGG CCC 540
      Cys His Cys Gly Lys Cys Asp Ser Asp Ser Thr Asp Cys Thr Val Arg Gly Leu Gly Pro

      570
AGC TAC TGC TCC TTT GGT GAA AAT TAA TCA GTG GAC ATT TC 600
      Ser Tyr Cys Ser Phe Gly Glu Met Lys Glu TAA
  
```

- 11 -

Still referring to the above sequence, there is a box around the ATG initiation codon of the 18 amino acid signal peptide, which is cleaved post-translationally. The mature protein begins with 5 the amino acid Asn encoded by the circled triplet AAT. The exon-intron boundaries are marked by arrows; they are flanked by the consensus sequence GT for the splice donor and AG for the splice acceptor site. There is a box around the stop codon TAA, the end of the coding 10 region.

Below is a reproduction of the above sequence not broken into triplets, showing restriction sites; the ATG beginning and the TAA ending the coding region are boxed and the exon-intron junctions are marked by arrows.

**SUBSTITUTE SHEET**

- 11a -

10 20 30 40 50 60  
 GCTTACATAA TCAATTATCT TCTTTGGTTT CTCAGTTTCT AGTGGGCTTC ATTGTTTCTT  
 D  
E  
I

70 80 90 100 110 120  
 TCCGAGACCA GGTGAGAG ACTCCAGTTT TTCTTCTTT TCTGTTGCTG GAAAGCAATC  
 S F N  
T I K B  
I I 2

130 140 150 160 170 180  
 TGCTGCAATA GCTGTGAGCT GACCAACATC ACCATTGCAA TAGAGAGAGA AGAATGTCTT  
 S A A  
V L U  
I I I

190 200 210 220 230 240  
 TTCTGCATAA GCATCAACAC CACTTGGTGT GCTGGCTACT GCTACACCAG GTAGGTACE  
 S  
F A I

250 260 270 280 290 300  
 ATCTTAG ACCAAGCAAT ATTCAATTTC TGTCTCAATT TGACTAAGCT AAATAAGGAC  
 D A L  
O U I

310 320 330 340 350 360  
 TTCCACAATA CCATAACCTA ACTCTCTTCT TAACTCTCTC AGCATCTCTT GTATAAGGAC  
 N  
B  
O 2

370 380 390 400 410 420  
 CCAGCCAGGC CCAGATCCA GAAACATCT ACCTTCAGGG AACTGCTATA TGAACAGTG  
 S A  
T U  
I I

430 440 450 460 470 480  
 AAGTGGGCTG GCTGTGCTCA CCATGAGAT TCTTTGATA CATACCCAGT GGCACCCGAG  
 M M M  
C F G P  
IA I M  
12 I I

490 500 510 520 530 540  
 ITGTCTCTGTG CCAAGTGTCA CAGCAGACAG ACTGATTGTA CTGTCCGAGG CETGGGCGCC  
 A  
S  
A  
I

550 560 570 580 590  
 AACTACTGCT CATTGCTGTA AATGAGGAA CAGGATCAG TGGACATTTC  
 A  
L  
U  
I

SUBSTITUTE SHEET

- 12 -

Insertion of the Beta FSH DNA into a BPV-Based Expression Vector

Referring to Fig. 3, a synthetic BamHI linker is inserted at the DdeI site of p15B6.8R/B, which is located 42 nucleotides 5' of the ATG initiation codon. Referring to Fig. 4, p15B6.8R/B is digested with DdeI and treated with E. coli DNA polymerase (Klenow), after which it is ligated to synthetic BamHI linkers and digested with BamHI. The 295 bp fragment containing the first exon of FSH is isolated and cloned into the BamHI site of pBR322. The resulting plasmid pBR295Bam is digested with KpnI plus EcoRI plus AvaI and ligated to p15B6.8R/B which has been digested with KpnI plus EcoRI plus SmaI. The ligation mix is then used to transform E. coli, and the plasmid pBR2.8Bam containing the human beta FSH DNA sequence as a BamHI fragment is identified from among the transformants by restriction mapping.

As shown in Fig. 4, expression plasmid CL28FSH2.8BPV is prepared according to the same method used to prepare pRF375 (Fig. 1), except that the 2.8 kb BamHI fragment of pBR2.8Bam is used in place of the alpha hCG cDNA clone. Plasmid CL28FSH2.8BPV can be used to transform mammalian host cells using conventional methods, and human beta FSH can be isolated and purified.

Transfection of Mouse Cells

To produce heterodimeric FSH using a mixed transfection, five ug of each BPV plasmid, i.e., pRF375 (alpha

subunit) and CL28FSH2.8BPV (beta FSH), are mixed and added 0.5 ml of a 250 mM CaCl<sub>2</sub> solution containing 10 ug of salmon sperm DNA as carrier. This mixture is bubbled into 0.5 ml 280 mM NaCl, 50 mM Hepes and 1.5 mM sodium phosphate. The 5 calcium phosphate precipitate is allowed to form for 30-40 minutes at room temperature.

24 hours prior to transfection,  $5 \times 10^5$  cells of mouse C127 cells (available from Dr. Dean Hamer, National Cancer Institute, NIH, Bethesda, MD) are placed in a 100 mm dish or 10 T-75 flask. Immediately before adding the exogenous DNA, the cells are fed with fresh medium (Dulbecco's Modified Medium, 10% fetal calf serum). One ml of calcium phosphate precipitate is added to each dish (10 ml), and the cells are incubated for 6-8 hours at 37°C.

15 The medium is aspirated and replaced with 5 ml of 2% glycerol in phosphate buffered saline, pH 7.0 (PBS) for 2 minutes at room temperature. The cells are washed with PBS, fed with 10ml of medium, and incubated at 37°C. After 20-24 hours, the medium is changed and subsequent refeeding of the 20 cells is carried out every 3-4 days. Individual clones are grown in T-25 flasks. After 7-21 days, cell clones can be transferred to larger flasks for analysis.

#### Deposits

The following, described above, has been deposited in 25 the Agricultural Research Culture Collection (NRRL), Peoria, IL 61604:



CL28FSH2.8BPV in E. coli, NRRL B-15923

The following, described above, has been deposited in the American Type Culture Collection, Rockville, MD:

PRF375 in C127 cells, ATCC CRL 8401;

5 Applicants' assignee, Integrated Genetics, Inc., acknowledges its responsibility to replace these cultures should they die before the end of the term of a patent issued hereon, and its responsibility to notify the ATCC and NRRL of the issuance of such a patent, at which time the deposits will  
10 be made available to the public. Until that time the deposits will be made available to the Commissioner of Patents under the terms of 37 CFR §1.14 and 35 USC §112.

Use

The transformed cell lines of the invention are used  
15 to produce glycosylated, biologically active heterodimeric human FSH, which is purified from the cells and/or their culture media using conventional purification techniques. FSH has a number of well-known medical uses associated with human fertility. For example, FSH can be used, alone or in  
20 conjunction with hCG or LH, to induce ovulation, or superovulation for in vitro fertilization.

In addition, heterodimeric FSH, or the beta subunit alone, can be used in diagnostic tests for fertility and pituitary functions.

FSH produced by recombinant cells has the advantage, compared to FSH obtained from natural sources, of being free from contamination by other human proteins, in particular other fertility hormones.

5 Other embodiments are within the following claims.

For example, rather than producing heterodimeric FSH by culturing cells containing two separate expression vectors, one encoding the alpha subunit and the other encoding the beta subunit, DNA encoding both subunits can be included in the same  
10 expression vector.

Claims

1. Biologically active heterodimeric human FSH, comprising an alpha subunit and a beta subunit, each said subunit being synthesized by a cell comprising an expression vector comprising heterologous DNA encoding said subunit.
- 5        2. The beta subunit of human FSH, synthesized by a cell comprising an expression vector comprising heterologous DNA encoding said beta subunit of FSH.
3. A cell comprising an expression vector, said cell being capable of producing the beta subunit of human FSH, said  
10 beta subunit of FSH being encoded by said expression vector.
4. The cell of claim 3, further comprising a second expression vector encoding the alpha subunit of said FSH.
5. The cell of claim 3, said cell being a mammalian cell.
- 15       6. The cell of claim 3, said vector comprising at least the 69% transforming region of the bovine papilloma virus genome.

7. The cell of claim 5, said cell being a mouse cell.
8. The expression vector of claim 3, said expression vector comprising a plasmid.
9. An expression vector encoding the beta subunit of  
5 human FSH.
10. The vector of claim 9, having NRRL Accession  
No. B-15923.
11. A method for producing the beta subunit of human  
FSH comprising culturing host cells comprising an expression  
10 vector encoding said beta subunit of FSH.
12. A method for producing biologically active,  
heterodimeric human FSH comprising culturing mammalian cells  
comprising a first expression vector encoding at least one  
subunit of said FSH.

13. The method of claim 12, the first subunit of said FSH being encoded by said first expression vector and the second subunit of said FSH being encoded by a second expression vector comprised in said host cell.

5 14. The method of claim 12, both subunits of said FSH being encoded by said first expression vector.





FIG 1



**FIG 2**




FIG 3






FIG 4

SUBSTITUTE SHEET

# INTERNATIONAL SEARCH REPORT

International Application No **PCT/US86/00223**

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC 4 <b>C07K 15/00 ; C12P 21/00 435/68; C12N 15/00 435/172</b> <b>260/112</b>		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched *		
Classification System	Classification Symbols	
<b>US</b>	<b>260/112</b> <b>435/68, 172.3, 317; 935/27, 29, 32, 13</b>	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> 14		
Category *	Citation of Document, 15 with indication, where appropriate, of the relevant passages 17	Relevant to Claim No. 18
<b>X</b>	<b>N, Fiddes et al 1980 'The cDNA for the B-subunit of human chorionic gonadotropin suggests evolution of a gene by read through into the 3'-untranslated region' Nature v286 p684-89</b>	<b>2,3,8,9,11,12</b>
<b>Y</b>	<b>N, Pierce et al 1981 "Glycoprotein Hormones: Structure and Function" Ann. Rev. Biochem. v50 p465-95</b>	<b>ALL</b>
<b>Y</b>	<b>N, Fiddes et al 1981 "The Gene Encoding the Common Alpha Subunit of the Four Human Glycoprotein Hormones" J. Mol. Appl. Gen. v1 p.3-18</b>	<b>ALL</b>
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: 15</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search *	Date of Mailing of this International Search Report *	
<b>April 16, 1986</b>	<b>25 APR 1986</b>	
International Searching Authority *	Signature of Authorized Officer 20	
<b>ISA/US</b>	<i>Joanne M. Giesser</i> <b>Joanne M. Giesser</b>	

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y	US,A, 4,468,464    Published 28 Aug. 1984 Cohen et al.	ALL
Y	US,A, 4,383,034    Published 10 May 1983 Sugimoto	ALL

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>10</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers ..... because they relate to subject matter <sup>12</sup> not required to be searched by this Authority, namely:

2. ☐ Claim numbers ..... because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out <sup>13</sup>, specifically:

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>11</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, <sup>16</sup> with Indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No <sup>18</sup>
Y	US A, 4,419,446 Published 6 Dec 1983 Howley et al	ALL
Y	GB A, 2,137,631 Published 10 Oct 1984 Celltech, Ltd	ALL